1 / 38

Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?. Activity Goals. Epidemiology: Ovarian Cancer. PARP and DNA Repair. BRCA and DNA Repair. Synthetic Lethality Is Associated With Inhibition of PARP in the Presence of BRCA Deficiency.

lane-levy
Télécharger la présentation

Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

  2. Activity Goals

  3. Epidemiology: Ovarian Cancer

  4. PARP and DNA Repair

  5. BRCA and DNA Repair

  6. Synthetic Lethality Is Associated With Inhibition of PARP in the Presence of BRCA Deficiency

  7. PARP Inhibition in BRCA-like Solid Tumors

  8. Repair Mechanisms and BRCAness

  9. BRCA Testing: When Should it Be Done?

  10. PARP Inhibition: Mechanism of Action

  11. Clinical Outcomes in Patients With BRCA Mutations

  12. PARP Inhibitors in Clinical Trials

  13. Case Study 1

  14. Treatment Options

  15. Anticipated PFS With Standard Treatment

  16. Olaparib as Maintenance Therapy: Study Design

  17. Results of BRCA Testing

  18. Results

  19. ASCO 2014: Cediranib/Olaparib

  20. PFS With Cediranib/Olaparib Superior to Olaparib Alone

  21. PFS Increased With Cediranib/Olaparib Combination

  22. Phase 2: PLD vs Olaparib

  23. Case Study 2

  24. Treatment Approach

  25. Neoadjuvant Chemotherapy (NACT) vs Primary Debulking Surgery (PDS)

  26. Dose-Dense Paclitaxel + Carboplatin vs Conventional Regimen

  27. BRCAness and Response to Chemotherapy

  28. GOG9923

  29. Key Issues for Future Developmentsof PARP Inhibitors

  30. Abbreviations

  31. References

  32. References (cont)

  33. References (cont)

  34. References (cont)

  35. References (cont)

  36. References (cont)

  37. References (cont)

More Related